Longevity Bros
Home › Glossary › HBOT (hyperbaric oxygen)
Glossary

HBOT: where hyperbaric oxygen is proven, and what the longevity studies actually showed

Hyperbaric oxygen is a real medical therapy with an approved list of indications and, since 2020, a longevity reputation built on a study of 35 people with no control group. Both facts matter.

Reviewed by the Longevity Bros team · Updated 1 October 2026

Before you read onResearch and educational information for adults, not medical advice. This entry explains one longevity term — what it means, why it matters and what the evidence says — and nothing here diagnoses, treats, cures or prevents any condition. Baseline labs come before anything, and your own physician has the final word. Longevity Bros offers coaching and written research protocols only — we do not sell, supply, source or ship any compound.

What it means

Hyperbaric oxygen therapy (HBOT) means breathing 100% oxygen in a chamber pressurised to 1.5–3 times atmospheric pressure, for 60–120 minutes per session. At that pressure, oxygen dissolves directly into plasma at 10–15 times the normal amount, reaching tissue that red cells cannot. Repeated sessions trigger a paradoxical "hyperoxic-hypoxic" response: the body reads the return to normal oxygen as relative hypoxia and responds with growth factors, new blood vessels and stem-cell mobilisation.

Soft-shell "mild hyperbaric" chambers at 1.3 atmospheres with air are a different and much weaker thing.

Why it matters for longevity

HBOT's approved uses — non-healing diabetic wounds, radiation tissue injury, carbon-monoxide poisoning, decompression sickness — are strongly evidenced. The longevity interest comes from Israeli studies reporting longer telomeres, fewer senescent cells and better cognition after 60 sessions. If those held up, HBOT would be the first therapy to shift hallmarks of ageing in humans.

What the evidence says

Approved indications: multiple randomised trials and Cochrane reviews support HBOT for diabetic foot ulcers (fewer amputations), late radiation injury and several others. That evidence is strong.

Longevity: Hachmo 2020 (35 adults over 64, 60 sessions at 2 ATA, no control group) reported telomere length up 20–38% and senescent T-cells down by a third in blood — a measure that shifts with blood-cell composition. Hadanny 2020 (63 adults, randomised) reported improved attention and processing speed and increased cerebral blood flow. Both are small, from one group, and neither measured a health outcome. No replication has yet appeared. Risks: ear barotrauma, transient myopia, oxygen toxicity seizures (rare), and the absolute contraindication of an untreated pneumothorax.

How to measure or use it

Related

Frequently asked questions

Does HBOT reverse ageing?

One uncontrolled study of 35 people reported longer blood-cell telomeres and fewer senescent cells. It has not been replicated, and no health outcome was measured.

Is a home soft chamber the same?

No. Soft chambers reach about 1.3 atmospheres on air; medical HBOT is 2–3 atmospheres on 100% oxygen. The physiology is different.

What are the risks?

Ear and sinus barotrauma, temporary short-sightedness, rare oxygen-toxicity seizures, and serious danger with an untreated collapsed lung. Screening is essential.

Your own protocol

Want this applied to your own numbers?

Fifteen minutes of intake, your labs, a human-reviewed protocol within about 24 hours, three documents, a free coach call and check-ins through the cycle. €399, follow-up included.

Build my protocol Book a 15-minute call